Evidence map›Paper›PMID 34641802›Full record

ArticleBMC infectious diseases2021

Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola.

Ariadna Rando-Segura, María Luisa Aznar, María Milagros Moreno, Mateu Espasa Soley, Elena Sulleiro Igual, Cristina Bocanegra Garcia, Eva Gil Olivas, Arlete Nindia Eugénio, Carlos Escartin Huesca, Adriano Zacarias and 8 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ariadna Rando-Segura *Microbiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain. a.rando@vhebron.net.
María Luisa Aznar *Infectious Disease Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
María Milagros MorenoHospital Nossa Senhora da Paz, Cubal, Angola.
Mateu Espasa SoleyMicrobiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.
Elena Sulleiro IgualMicrobiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.
Cristina Bocanegra GarciaInfectious Disease Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
Eva Gil OlivasInfectious Disease Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arlete Nindia EugénioHospital Nossa Senhora da Paz, Cubal, Angola.
Carlos Escartin HuescaMicrobiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.
Adriano ZacariasHospital Nossa Senhora da Paz, Cubal, Angola.
Josep Vegue ColladoMicrobiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.
Domingos KatimbaHospital Nossa Senhora da Paz, Cubal, Angola.
Maria Carmen Vivas CanoMicrobiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.
Estevao GabrielHospital Nossa Senhora da Paz, Cubal, Angola.
Maria Teresa López GarcíaHospital Nossa Senhora da Paz, Cubal, Angola.
Tomas Pumarola SuñeMicrobiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.
Israel Molina RomeroInfectious Disease Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
María Teresa Tórtola FernándezMicrobiology Department, Vall d'Hebron University Hospital, PROSICS Barcelona, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119 - 129, 08035, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe importance of Mycobacterium tuberculosis strains with disputed rpoB mutations remains to be defined. This study aimed to assess the frequency and types of rpoB mutations in M. tuberculosis isolates from Cubal, Angola, a country with a high incidence of tuberculosis.

methodsAll isolates included (n = 308) were analyzed using phenotypic drug susceptibility testing and GenoType MTBDRplus assay. DNA sequencing of the rpoB gene and determination of rifampicin MIC by macrodilution method were additionally performed on isolates yielding discordant results (n = 12) and those in which the mutation detected was not characterized (n = 8).

resultsIn total, 85.1% (74/87) of rifampicin-resistant strains had undisputed rpoB mutations -S450L (49), D435V (15), H445D (3), H445Y (2), Q432ins (1), L449M plus S450F (1), S450F (1), S450W (1) and S450Y (1)-; 10.3% (9/87) had disputed rpoB mutations-L430P plus S493L (1), N437del (1), H445L (3), D435Y (2), L452P (2)-, 2.3% (2.3%) showed no rpoB mutations and 2.3% (2/87) showed heteroresistance-D435Y plus L452P and L430P plus S493L-.

conclusionDisputed rpoB mutations were common, occurring in 10.3% of rifampicin resistant isolates. Current phenotyping techniques may be unable to detect this resistance pattern. To increase their sensitivity, a lower concentration of RIF could be used in these tests or alternatively, rpoB mutations could be screened and characterized in all M. tuberculosis strains.

Indexed as

Mycobacterium tuberculosisTuberculosisAngolaBacterial ProteinsDNA-Directed RNA PolymerasesDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMutationBacterial ProteinsDNA-Directed RNA PolymerasesAngolaCubalGenoType MTBDRplus VER2.0ResistanceRifampicinrpoB mutations

Identifiers

PMID34641802
PMCPMC8507306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.